Eteplirsen Approval Reflected FDA's Conflict On Accelerated Approval – Former Sarepta CEO
Executive Summary
There is anxiety within the US agency over use of the pathway amid the prospect for confirmatory trials to fail, former CEO Garabedian says at FDA/CMS Summit.